PPM1D as a driver and pharmacological target in clonal hematopoiesis

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F19%3A00502886" target="_blank" >RIV/68378050:_____/19:00502886 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
PPM1D as a driver and pharmacological target in clonal hematopoiesis
Original language description
Chemotherapy or radiotherapy cause genotoxic stress that kills cancer cells and ideally only tolerable DNA damage to the neighboring healthy tissues. Cell fate after exposure to genotoxic stress is determined by the tumor suppressor p53 that controls transcription of both pro-survival and pro-apoptotic genes. Depending on the DNA damage load, cells activate the cell cycle checkpoint arrest or die through programmed cell death. Protein phosphatase 2C delta (referred to as WIP1) is a negative regulator of p53 and has been proposed as potential pharmaceutical target. Recently, mutations in PPM1D were observed in patients that developed secondary cancer after receiving a chemotherapy. This review will discuss the role of PPM1D in development of the secondary cancers as well as potential use of small-molecule inhibitors as prevention to causing these adverse effects of chemotherapy.
Czech name
—
Czech description
—

Project
<a href="/en/project/LO1220" target="_blank" >LO1220: CZ-OPENSCREEN: National infrastructure for chemical biology</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)